Castle Biosciences Inc

XNAS:CSTL

25.50

+1.29 (+5.33%)

5:55:28 PM EDT: $25.51 +0.01 (+0.04%)

Market Cap (Intraday)	779.14M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$71.07 Million
Adjusted EPS	-$0.52

See more estimates

10-Day MA	$24.09
50-Day MA	$23.07
200-Day MA	$21.06

See more pivots

Castle Biosciences Inc Stock, XNAS:CSTL

505 South Friendswood Drive, Suite 401, Friendswood, Texas 77546

United States of America

Phone: +1.866.788.9007

Number of Employees: 761

http://www.castlebiosciences.com

Description

Castle Biosciences, Inc. is a commercial-stage dermatological cancer company, which engages in the provision of genomic information for physicians and patients. The firm offers DecisionDx-Melanoma, a proprietary multi-gene expression profile (GEP) test that predicts the risk of metastasis and recurrence for patients diagnosed with invasive cutaneous melanoma. It also markets DecisionDx-UM, Decision Dx DiffDx-Melanoma, DecisonDx-CMSeq, DecisionDx-SCC, DecsionDx-UMSeq, and DecisonDX-PRAME. The company was founded by Derek J. Maetzold in September 2007 and is headquartered in Friendswood, TX.